GMP-conformant on-site manufacturing of a CD133+ stem cell product for cardiovascular regeneration. - Wikidata - wikimedia - TriplyDB

GMP-conformant on-site manufacturing of a CD133+ stem cell product for cardiovascular regeneration.

GMP-conformant on-site manufacturing of a CD133+ stem cell product for cardiovascular regeneration.

http://www.wikidata.org/entity/Q37637078

about

Data on the fate of MACS® MicroBeads intramyocardially co-injected with stem cell products Delivering advanced therapies: the big pharma approach.Recent Progress in Stem Cell Modification for Cardiac Regeneration.

P2860

Q38679832-27E2603F-03D1-4627-8C5F-1BA138EA7A44 Q39454312-D2803072-D6A9-4109-A76F-01A8CEBA4D20 Q52657125-36F15D26-43AB-4F17-B563-B743638DA994

P2860

GMP-conformant on-site manufacturing of a CD133+ stem cell product for cardiovascular regeneration.

http://www.wikidata.org/entity/Q37637078

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 10 February 2017

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

GMP-conformant on-site manufac ...... r cardiovascular regeneration.

@en

GMP-conformant on-site manufac ...... r cardiovascular regeneration.

@nl

type

label

GMP-conformant on-site manufac ...... r cardiovascular regeneration.

@en

GMP-conformant on-site manufac ...... r cardiovascular regeneration.

@nl

prefLabel

GMP-conformant on-site manufac ...... r cardiovascular regeneration.

@en

GMP-conformant on-site manufac ...... r cardiovascular regeneration.

@nl

P1433

Q37637078-3570A818-44E1-4952-92E3-DD31AD16B639

P1476

Q37637078-307A1C2B-8ADF-4E84-8374-A6BAE5CE7287

P2093

Q37637078-038BDFB9-A43D-4362-B822-86FF3849EF4D

Q37637078-0615A1C8-742D-4C66-9D34-FAC12D3599DA

Q37637078-0844D87B-36E7-41A4-9F9E-11BD384F47C3

Q37637078-185064E9-72D7-4E1B-9531-9C09D4741D47

Q37637078-1A4EC3C0-BF32-43A5-8F29-CCAB8853AC8B

Q37637078-21415B8B-669F-4333-AB3F-106DE4DAD116

Q37637078-2CCED29E-EBC0-42CD-9261-D55D299EFA8B

Q37637078-361AEE0C-3AA2-4758-BBA5-17A57823F7F0

Q37637078-4C02B033-D110-4C2D-8513-B7AE631A5D13

Q37637078-684A14A1-01A2-48A5-8854-B5A3B8248BF3

P2860

Q37637078-02263ADB-0B43-4FE8-A40C-06B4B0C2E528

Q37637078-10772B61-0222-47B4-8D39-02D46F014523

Q37637078-33C521E1-8586-40EA-8DD0-14F8E40F30C2

Q37637078-379DDEFF-761A-409B-86C7-5FF7EF77ABDE

Q37637078-3D054E9A-F2DB-4741-986E-495B8686BF9F

Q37637078-40F9158D-845D-49D4-92E8-996704C1651E

Q37637078-434CC90A-93C3-4B1D-8CA3-A837B7ABCED3

Q37637078-44C99E2E-F43A-4921-ADA6-0E8EB1D517FE

Q37637078-52D8F945-B7D2-4DDF-9D02-C3FFA353DA36

Q37637078-5BC7DF68-3941-4787-80DD-37C708C7C186

P2888

Q37637078-BD61968A-6763-4DE5-9300-61979ADE927A

P304

Q37637078-207FF53F-BF7B-4196-A666-CD62C6DE2AAB

P31

Q37637078-CF5FFFBB-5059-4AD3-ABA4-7F8E7CD97EA2

P356

Q37637078-4D891B13-DF24-493A-AFB3-5F06489AA1EC

P433

Q37637078-0F661E3D-C9C6-4B7B-AB47-4BA6E1A2CC9A

P478

Q37637078-8F576CD9-92D9-49DC-9C75-2AF39DB0987E

P577

Q37637078-C1C4EB1B-C704-48F5-B55F-422527333DE1

P6179

Q37637078-6352CF76-5676-481C-BCC1-A8B2F1995B46

P698

Q37637078-6F5F0478-2F8F-46EC-BD66-0B40AAC12601

P932

Q37637078-3E7E3CEE-BD11-4D49-A970-17145E4EC728

P356

S13287-016-0467-0

P1433

Stem Cell Research & Therapy

P1476

GMP-conformant on-site manufac ...... r cardiovascular regeneration.

@en

P2093

Anna Skorska

http://www.w3.org/2001/XMLSchema#string

Cornelia A Lux

http://www.w3.org/2001/XMLSchema#string

Frauke Hausburg

http://www.w3.org/2001/XMLSchema#string

Gudrun Tiedemann

http://www.w3.org/2001/XMLSchema#string

Gustav Steinhoff

http://www.w3.org/2001/XMLSchema#string

Heiko Lemcke

http://www.w3.org/2001/XMLSchema#string

Jana Große

http://www.w3.org/2001/XMLSchema#string

Manuela Bastian

http://www.w3.org/2001/XMLSchema#string

Nicole Zarniko

http://www.w3.org/2001/XMLSchema#string

Paula Müller

http://www.w3.org/2001/XMLSchema#string

P2860

Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration

Safety and efficacy of bone marrow-derived autologous CD133+ stem cell therapy.

Red blood cell contamination of the final cell product impairs the efficacy of autologous bone marrow mononuclear cell therapy.

Preliminary evaluation of a highly automated instrument for the selection of CD34+ cells from mobilized peripheral blood stem cell concentrates

Bone marrow derived stem cells in regenerative medicine as advanced therapy medicinal products.

Analyzing migratory properties of human CD133(+) stem cells in vivo after intraoperative sternal bone marrow isolation.

The CD34 antigen: structure, biology, and potential clinical applications.

Full GMP-compliant validation of bone marrow-derived human CD133(+) cells as advanced therapy medicinal product for refractory ischemic cardiomyopathy.

Effect of transendocardial delivery of autologous bone marrow mononuclear cells on functional capacity, left ventricular function, and perfusion in chronic heart failure: the FOCUS-CCTRN trial

Ligand-dependent development of the endothelial and hemopoietic lineages from embryonic mesodermal cells expressing vascular endothelial growth factor receptor 2.

P2888

s13287-016-0467-0

P304

33

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S13287-016-0467-0

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P577

2017-02-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1083762396

http://www.w3.org/2001/XMLSchema#string

P698

28187777

http://www.w3.org/2001/XMLSchema#string

P932

5303262

http://www.w3.org/2001/XMLSchema#string